A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Here are four things to know. 1. Biktarvy is a once-daily, triple-combination tablet used to treat HIV infections. 2. The drug’s wholesale price will be about $36,000 per year, which falls in line ...

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

A few weeks ago, Grant Ogren and Rhea Ashby-Durall, the executive director and the outreach manager of SAN (formerly Spokane AIDS Network), met with their representative from Gilead Sciences, the ...

SYDNEY, Australia (WKRC) - Researchers believe a possible HIV cure is nearing reality after a "previously impossible discovery." According to The New York Post, citing a results published in the ...

Modern-day HIV treatments may stem from a genetic mutation dating back to the Viking Age, researchers said. Steinar Engeland via Unsplash On June 5, 1981, the Centers for Disease Control and ...